Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGN 101

Next Previous
X
Search
Drug Profile

IGN 101

Alternative Names: Cancer vaccine (IGN101) - Aphton; Cancer vaccine - Igeneon

Latest Information Update: 17 Jun 2015

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Developer Altropus
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 05 Nov 2009 Clinical development is ongoing in Europe
  • 03 Jun 2008 Efficacy data from a Phase II/III trial in Non-small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 07 Feb 2006 Pending directorship approval, Igeneon intends give Celltrion the right of first refusal to further develop and commercialise IGN 101

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top